News & Updates

In men with nonmetastatic castration-resistant prostate cancer (M0CRPC), the prostate-specific antigen (PSA) doubling time and the time to castration resistance (TTCRPC) predict cancer-specific survival (CSS), a recent study has found.

Maintenance therapy with the PARP* inhibitor niraparib led to a sustained and durable progression-free survival (PFS), regardless of biomarker status, in patients with primary advanced ovarian cancer who responded to platinum-based chemotherapy, an updated analysis of the phase III PRIMA/ENGOT-OV26/GOG-3012 trial has shown.

The benefit of deucravacitinib in moderate to severe plaque psoriasis was demonstrated in a population of Asian patients, according to results of the phase III POETYK PSO-3 trial.

Poorly controlled glycosylated haemoglobin (HbA1c) levels appear to aggravate the risk of mortality in patients with type 2 diabetes (T2D) and chronic kidney disease (CKD), a recent study has found. Glycaemic control is not associated with progression to end-stage kidney disease (ESKD).

In the updated analysis of the POSEIDON trial presented at ESMO 2022, the combination regimen comprising tremelimumab, durvalumab, and chemotherapy (T+D+CT) used in the first-line setting conferred long-term overall survival (OS) benefit in individuals with metastatic non-small-cell lung cancer (mNSCLC).